Clear Cell Renal Cell Carcinoma

P2, N=25, Recruiting, Sun Yat-sen University

Importantly, blocking the PSA-CD56/Siglec-7 interaction with specific antibodies restored T cell effector functions and triggered apoptosis of ccRCC cells. Our study unveils the PSA-CD56/Siglec-7 axis as a novel glyco-immune checkpoint, which represents a promising target for therapeutic interventions in ccRCC.

Nine of these genes showed significant prognostic relevance. The current work identifies key biomarkers that can enhance ccRCC diagnosis and guide future therapy.

P2, N=21, Recruiting, Sun Yat-sen University

Together, this study underscores the coordinated role of HIFα and ZNF395 in shaping metabolic adaptations in response to hypoxia in VHL-deficient ccRCCs. ZNF395 and HIF are complementary mediators of hypoxia-induced metabolic reprogramming and therapeutic targets in VHL-deficient kidney cancer, with the former regulating glutamine metabolism and the latter regulating glucose metabolism.

As reported, ongoing phase III clinical trials are set to yield potentially practice-changing results, investigating innovative combinatorial strategies including belzutifan. Ongoing advancement of predictive biomarkers and understanding of resistance mechanisms could improve patient selection and identify new drug targets, thereby increasing the clinical efficacy of belzutifan.

Transcriptomic analysis revealed that high RENALNet risk was associated with gene expression signatures enriched in pathways such as epithelial-mesenchymal transition, IL6-JAK-STAT3 signaling, and PI3K-Akt signaling, highlighting its link to tumor aggressiveness. RENALNet thus offers a biologically interpretable framework for risk stratification in ccRCC, supporting surgical decision-making and advancing the integration of radiogenomic deep learning into precision oncology.

Despite extensive prior treatment, patients experienced clinical benefit from TT, particularly VEGFR-TKIs, after progression on belzutifan. These findings support the feasibility of sequencing TT following belzutifan-based regimens in advanced ccRCC, and highlight the need to further define optimal therapeutic sequencing strategies.

P3, N=718, Not yet recruiting, SWOG Cancer Research Network

By expanding upon the foundation established by belzutifan, the field is poised for further therapeutic advances.

[18F]AlF-NYM005 PET/CT was superior to [18F]FDG in the detection of renal tumours and metastatic lesions, demonstrating higher radiotracer uptake and more accurate staging.

P3, N=861, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed